

Amendment No. 612

Senate Amendment to Assembly Bill No. 188	(BDR 40-567)
<b>Proposed by:</b> Senate Committee on Health and Human Services	
<b>Amends:</b> Summary: No Title: Yes Preamble: Add Joint Sponsorship: Yes Digest: Yes	

ASSEMBLY ACTION			Initial and Date	SENATE ACTION			Initial and Date		
Adopted	<input type="checkbox"/>	Lost	<input type="checkbox"/>	_____	Adopted	<input type="checkbox"/>	Lost	<input type="checkbox"/>	_____
Concurred In	<input type="checkbox"/>	Not	<input type="checkbox"/>	_____	Concurred In	<input type="checkbox"/>	Not	<input type="checkbox"/>	_____
Receded	<input type="checkbox"/>	Not	<input type="checkbox"/>	_____	Receded	<input type="checkbox"/>	Not	<input type="checkbox"/>	_____

EXPLANATION: Matter in (1) *blue bold italics* is new language in the original bill; (2) variations of green bold underlining is language proposed to be added in this amendment; (3) ~~red strikethrough~~ is deleted language in the original bill; (4) ~~purple double strikethrough~~ is language proposed to be deleted in this amendment; (5) orange double underlining is deleted language in the original bill proposed to be retained in this amendment.

EWR/AAK



Date: 5/23/2023

A.B. No. 188—Revises provisions governing investigational treatments.  
(BDR 40-567)





ASSEMBLY BILL NO. 188—ASSEMBLYMEN KASAMA; GRAY, GURR, HIBBETTS,  
KOENIG, THOMAS AND YUREK

FEBRUARY 20, 2023

JOINT SPONSORS: SENATORS OHRENSCHALL; ~~[AND]~~ DONDERO LOOP, KRASNER AND  
STONE

Referred to Committee on Health and Human Services

SUMMARY—Revises provisions governing investigational treatments.  
(BDR 40-567)FISCAL NOTE: Effect on Local Government: Increases or Newly Provides for  
Term of Imprisonment in County or City Jail or Detention  
Facility.  
Effect on the State: No.

~

EXPLANATION – Matter in *bolded italics* is new; matter between brackets ~~[omitted material]~~ is material to be omitted.

AN ACT relating to health care; revising the circumstances under which a physician is authorized to prescribe or recommend and a manufacturer is authorized to provide or make available an investigational drug, biological product or device; authorizing a manufacturer to provide or make available an individualized investigational treatment to a patient under certain circumstances; requiring the reporting of certain information concerning individualized investigational treatments and investigational drugs, biological products and devices to certain governmental entities; authorizing the imposition of administrative penalties for certain violations; prohibiting an officer, employee or agent of this State from preventing or attempting to prevent a patient from accessing ~~[such]~~ an individualized investigational treatment; authorizing a physician to prescribe or recommend an individualized investigational treatment under certain circumstances; providing a penalty; and providing other matters properly relating thereto.

**Legislative Counsel's Digest:**

Existing federal law prohibits the introduction of a drug or biological product into interstate commerce if the drug or biological product has not received approval from the United States Food and Drug Administration. (21 U.S.C. § 355; 42 U.S.C. § 262) Existing federal regulations allow expanded access to investigational drugs and biological products for patients who have a life-threatening or severely debilitating disease or condition, or a serious or immediately life-threatening illness, under certain circumstances. (21 C.F.R. Part 312,

Subparts E and I) Existing Nevada law authorizes the manufacturer of an investigational drug, biological product or device, upon the prescription or recommendation of a physician, to provide or make available the investigational drug, biological product or device to a patient who has been diagnosed with a terminal condition that will, without the administration of life-sustaining treatment, result in death within 1 year. (NRS 454.690) Existing law authorizes a physician to issue a prescription or recommendation for an investigational drug, biological product or device if the physician has: (1) diagnosed the patient with a terminal condition; (2) consulted with the patient and the patient and physician have determined that no treatment currently approved by the United States Food and Drug Administration is adequate to treat the terminal condition; and (3) obtained informed, written consent to the use of the investigational drug, biological product or device from the patient or his or her representative, parent or guardian. (NRS 630.3735, 633.6945) **Sections 2, 4 and 7** of this bill: (1) remove the requirement that a patient be diagnosed with a terminal condition before a physician is authorized to prescribe or recommend, and a manufacturer is authorized to provide, an investigational drug, biological product or device; and (2) instead require the patient to be diagnosed with a life-threatening or severely debilitating disease or condition before such actions are authorized. **Section 2** additionally: (1) authorizes the manufacturer of an individualized investigational treatment to make the treatment available to such a patient under similar conditions to an investigational drug, biological product or device if the manufacturer operates in a facility that meets certain federal requirements for the protection of human subjects; and (2) defines "individualized investigational treatment" to mean a drug, biological product or device that is unique to and produced exclusively for use by an individual patient based on the genetic profile of the patient. **Sections 4 and 7** authorize a physician to prescribe or recommend an individualized investigational treatment under similar conditions to those under which a physician is authorized to recommend an investigational drug, biological product or device, except that **sections 4 and 7** require the physician to additionally conduct certain biochemical analyses.

**Section 2 requires a manufacturer that provides or makes available an individualized investigational treatment or investigational drug, biological product or device to establish a hotline for patients who develop adverse effects or symptoms. Section 2 also requires such a manufacturer to submit quarterly reports to the Board of Medical Examiners and the State Board of Osteopathic Medicine summarizing the individualized investigational treatments or investigational drugs, biological products or devices provided to patients of physicians who are licensed by those boards. Section 2 establishes an administrative penalty to be imposed against a manufacturer that fails to submit the required report.** **Section 2** also provides that if a patient dies while being treated with an individualized investigational treatment or investigational drug, biological product or device, the heir or heirs of the deceased patient are not personally liable for any outstanding debt related to such treatment.

Existing law makes it a misdemeanor for any officer, employee or agent of this State to prevent or attempt to prevent a patient from accessing an investigational drug, biological product or device if certain requirements are met. (NRS 454.690) **Section 2** additionally: (1) provides that counseling, advice or a recommendation from a physician consistent with medical standards of care is not a violation; and (2) makes it a misdemeanor for such an officer, employee or agent to prevent or attempt to prevent a patient from accessing an individualized investigational treatment if the same requirements are met.

**Sections 4 and 7 revise the requirements concerning the informed, written consent that a physician is required to obtain before prescribing or recommending an individualized investigational treatment or an investigational drug, biological product or device. Sections 4 and 7 also require a physician who prescribes or recommends an individualized investigational treatment or an investigational drug, biological product or device to provide the patient with a form that contains certain information concerning: (1) the individualized investigational treatment or investigational drug, biological product or device; and (2) the treatment of adverse effects or symptoms caused by the individualized investigational treatment or investigational drug, biological product or device. Sections 4 and 7 require such a physician to report to the Board of Medical Examiners or the State Board of Osteopathic Medicine, as appropriate, if a patient dies or is hospitalized as the result of using an individualized investigational treatment or investigational drug, biological product or device. Sections 4 and 7 require those boards**

to submit to the Legislature a biennial summary of the information reported to those boards pursuant to sections 2, 4 and 7 concerning individualized investigational treatments and investigational drugs, biological products and devices. Sections 4 and 7 additionally authorize those boards to adopt regulations to ensure the safety and efficacy of individualized investigational treatments and investigational drugs, biological products and devices.

Existing law: (1) generally makes it a misdemeanor for any person to possess, procure, obtain, process, produce, derive, manufacture, sell, offer for sale, give away or otherwise furnish any drug which may not be lawfully introduced into interstate commerce under the Federal Food, Drug and Cosmetic Act; and (2) exempts from that criminal penalty a person who engages in certain acts to make an investigational drug or biological product available when certain requirements are met. (NRS 454.351) **Section 1** of this bill additionally exempts from the criminal penalty a manufacturer who provides an individualized investigational treatment.

Existing law provides that a physician or person engaged in the practice of professional nursing who procures or administers a controlled substance or dangerous drug is not subject to professional discipline if the controlled substance or dangerous drug is an investigative drug or biological product prescribed by a physician. (NRS 630.306, 632.347, 633.511) **Sections 3, 5 and 6** of this bill additionally exempt such persons from professional discipline if the substance is an individualized investigational treatment.

**Section 8 of this bill provides that the provisions of this bill expire on July 1, 2027. Section 7.5 of this bill authorizes a patient who is being treated with an individualized investigational treatment or an investigational drug, biological product or device on June 30, 2027, to continue to receive such treatment on and after July 1, 2027, regardless of whether the patient remains eligible to receive such treatment.**

**WHEREAS, As dedicated providers of health care committed to providing the highest standard of care, physicians are required to adhere to federal regulations governing the informed consent of patients; and**

**WHEREAS, The provisions of 45 C.F.R. § 46.116 establish requirements concerning the provision of written or oral informed consent by human subjects of research; and**

**WHEREAS, To ensure ethical research practices, 45 C.F.R. § 46.116 requires an investigator to obtain legally effective informed consent from each human subject of research or the subject's legally authorized representative; and**

**WHEREAS, Such informed consent should be obtained under circumstances that allow the person providing informed consent sufficient opportunity to engage in discussions and consider participation while minimizing the potential for coercion and undue influence; and**

**WHEREAS, Information provided to a person from whom such informed consent is sought must be conveyed in a language that is understandable to that person; and**

**WHEREAS, Effective communication is crucial to ensure that the person from whom such informed consent is sought fully comprehends the nature of the research, the potential risks and benefits of participating in the research and the alternatives to such participation in order to make an informed decision concerning such participation; and**

**WHEREAS, By adhering to the provisions of 45 C.F.R. § 46.116, physicians and investigators demonstrate their commitment to the principles of patient autonomy, respect for patients and promoting the welfare of patients; and**

**WHEREAS, Informed consent serves as a cornerstone of the ethical practice of medicine and osteopathic medicine by promoting transparency, trust and collaboration between physicians and their patients; now, therefore,**

THE PEOPLE OF THE STATE OF NEVADA, REPRESENTED IN  
SENATE AND ASSEMBLY, DO ENACT AS FOLLOWS:

**Section 1.** NRS 454.351 is hereby amended to read as follows:

454.351 1. Any person within this State who possesses, procures, obtains, processes, produces, derives, manufactures, sells, offers for sale, gives away or otherwise furnishes any drug which may not be lawfully introduced into interstate commerce under the Federal Food, Drug and Cosmetic Act is guilty of a misdemeanor.

2. The provisions of this section do not apply:

(a) To physicians licensed to practice in this State who have been authorized by the United States Food and Drug Administration to possess experimental drugs for the purpose of conducting research to evaluate the effectiveness of such drugs and who maintain complete and accurate records of the use of such drugs and submit clinical reports as required by the United States Food and Drug Administration.

(b) To any substance which has been licensed by the State Board of Health for manufacture in this State but has not been approved as a drug by the United States Food and Drug Administration. The exemption granted in this paragraph does not grant authority to transport such a substance out of this State.

(c) To any person or governmental entity who possesses, procures, obtains, processes, produces, derives, manufactures, sells, offers for sale, gives away or otherwise furnishes an *individualized investigational treatment or* investigational drug or biological product when authorized pursuant to NRS 454.690.

(d) To any physician who prescribes or recommends an *individualized investigational treatment or* investigational drug or biological product pursuant to NRS 630.3735 or 633.6945.

3. As used in this section:

(a) "Biological product" has the meaning ascribed to it in NRS 454.690.

(b) *"Individualized investigational treatment" has the meaning ascribed to it in NRS 454.690.*

(c) "Investigational drug or biological product" means a drug or biological product that:

(1) Has successfully completed Phase 1 of a clinical trial;

(2) Has not been approved by the United States Food and Drug Administration; and

(3) Is currently being tested in a clinical trial that has been approved by the United States Food and Drug Administration.

**Sec. 2.** NRS 454.690 is hereby amended to read as follows:

454.690 1. The manufacturer of an investigational drug, biological product or device may provide or make available the investigational drug, biological product or device to a patient in this State who has been diagnosed with a ~~terminal~~ *life-threatening or severely debilitating disease or* condition if a physician has prescribed or recommended the investigational drug, biological product or device to the patient as authorized pursuant to NRS 630.3735 or 633.6945.

2. *The manufacturer of an individualized investigational treatment may provide or make available the individualized investigational treatment to a patient in this State who has been diagnosed with a life-threatening or severely debilitating disease or condition if:*

(a) *The manufacturer operates within a health care institution that:*

(1) *Operates under a Federalwide Assurance for the protection of human subjects pursuant to 45 C.F.R. Part 46; and*

(2) *Is subject to all Federalwide Assurance regulations, policies and guidelines, including, without limitation, renewals and updates; and*

(b) *A physician has prescribed or recommended the individualized investigational treatment to the patient as authorized pursuant to NRS 630.3735 or 633.6945.*

3. A manufacturer who provides or makes available an *individualized investigational treatment or* investigational drug, biological product or device to a patient pursuant to subsection 1 *or 2* may:

(a) Provide the *individualized investigational treatment or* investigational drug, biological product or device, *as applicable*, to the patient without charge; or

(b) Charge the patient only for the costs associated with the manufacture of the *individualized investigational treatment or* investigational drug, biological product or device ~~(-)~~, *as applicable*.

~~(3-)~~ 4. *A manufacturer that provides or makes available an individualized investigational treatment or investigational drug, biological product or device to a patient pursuant to subsection 1 or 2 shall:*

*(a) Establish a hotline that operates 24 hours a day, 7 days a week, including holidays, for patients who develop adverse effects or symptoms.*

*(b) On or before January 1, April 1, July 1 and October 1 of each year, or, if that date falls on a Saturday, Sunday or legal holiday, the next business day thereafter, submit to the Board of Medical Examiners and the State Board of Osteopathic Medicine a report summarizing information concerning the individualized investigational treatments or the investigational drugs, biological products or devices provided or made available to patients of physicians licensed by the board to which the report is submitted during the immediately preceding calendar quarter. The report must include, without limitation:*

*(1) The number of patients who received the individualized investigational treatment or the investigational drug, biological product or device;*

*(2) Where applicable, the average number of doses received by patients;*

*(3) The name of the individualized investigational treatment or the investigational drug, biological product or device and, where applicable, the investigational new drug number assigned by the United States Food and Drug Administration;*

*(4) The disease or condition that the individualized investigational treatment or the investigational drug, biological product or device is intended to treat;*

*(5) The uses for which the individualized investigational treatment or the investigational drug, biological product or device was provided or made available; and*

*(6) Any known adverse effects or symptoms associated with the administration of the individualized investigational treatment or the investigational drug, biological product or device.*

5. An officer, employee or agent of this State shall not prevent or attempt to prevent a patient from accessing an *individualized investigational treatment or* investigational drug, biological product or device that is authorized to be provided or made available to a patient pursuant to this section. *Counseling, advice or a recommendation from a physician consistent with medical standards of care is not a violation of this subsection.*

~~(4-5-)~~ 6. *This section does not create a private cause of action against the manufacturer of an individualized investigational treatment or investigational drug, biological product or device, or against any other person or entity involved in the care of a patient who uses an individualized investigational treatment or investigational drug, biological product or device for any harm done to the*

1 patient resulting from the individualized investigational treatment or  
2 investigational drug, biological product or device, if the manufacturer or other  
3 person or entity is complying in good faith with the provisions of this section and  
4 has exercised reasonable care.

5 ~~6-7~~ 7. Notwithstanding any provision of law to the contrary, if a patient  
6 dies while being treated with an individualized investigational treatment or  
7 investigational drug, biological product or device, the heir or heirs of the  
8 deceased patient must not be held personally liable for any outstanding debt  
9 related to such treatment.

10 ~~7-8~~ 8. A violation of any provision of this section, except for subsection 4,  
11 is a misdemeanor.

12 ~~5-8~~ 9. If a manufacturer fails to comply with the provisions of subsection  
13 4 and such failure is not caused by excusable neglect, technical problems or other  
14 extenuating circumstances, the manufacturer is liable for a civil penalty to be  
15 recovered by the Attorney General in an amount of \$5,000 for each day of such  
16 failure. The Attorney General shall deposit any civil penalties collected pursuant  
17 to this subsection with the State Treasurer for credit to the State General Fund.

18 10. As used in this section:

19 (a) "Biological product" has the meaning ascribed to it in 42 U.S.C. § 262.

20 (b) *"Individualized investigational treatment" means a drug, biological*  
21 *product or device that is unique to and produced exclusively for use by an*  
22 *individual patient based on the genetic profile of the patient, including, without*  
23 *limitation, by an analysis of the genomic sequence of the patient, human*  
24 *chromosomes, deoxyribonucleic acid, ribonucleic acid, genes, gene products such*  
25 *as enzymes and other types of proteins or metabolites. The term includes, without*  
26 *limitation, individualized gene therapy, antisense oligonucleotides and*  
27 *individualized neoantigen vaccines.*

28 (c) "Investigational drug, biological product or device" means a drug,  
29 biological product or device that:

30 (1) Has successfully completed Phase 1 of a clinical trial;

31 (2) Has not been approved by the United States Food and Drug  
32 Administration; and

33 (3) Is currently being tested in a clinical trial that has been approved by the  
34 United States Food and Drug Administration.

35 ~~[(e) "Terminal condition" means an incurable and irreversible condition that,~~  
36 ~~without the administration of life sustaining treatment, will, in the opinion of the~~  
37 ~~attending physician, result in death within 1 year.]~~

38 ~~[(d) "Life-threatening disease or condition" means a disease or condition~~  
39 ~~that has a high likelihood of death unless the course of the disease or condition is~~  
40 ~~interrupted.] has the meaning ascribed to it in 21 C.F.R. § 312.81, as interpreted~~  
41 ~~by any guidance of the United States Food and Drug Administration.~~

42 ~~[(e) "Severely debilitating disease or condition" means a disease or condition~~  
43 ~~that causes major irreversible morbidity.] has the meaning ascribed to it in 21~~  
44 ~~C.F.R. § 312.81, as interpreted by any guidance of the United States Food and~~  
45 ~~Drug Administration.~~

46 Sec. 3. NRS 630.306 is hereby amended to read as follows:

47 630.306 1. The following acts, among others, constitute grounds for  
48 initiating disciplinary action or denying licensure:

49 (a) Inability to practice medicine with reasonable skill and safety because of  
50 illness, a mental or physical condition or the use of alcohol, drugs, narcotics or any  
51 other substance.

52 (b) Engaging in any conduct:

53 (1) Which is intended to deceive;



1 (2) Which the Board has determined is a violation of the standards of  
2 practice established by regulation of the Board; or

3 (3) Which is in violation of a provision of chapter 639 of NRS, or a  
4 regulation adopted by the State Board of Pharmacy pursuant thereto, that is  
5 applicable to a licensee who is a practitioner, as defined in NRS 639.0125.

6 (c) Administering, dispensing or prescribing any controlled substance, or any  
7 dangerous drug as defined in chapter 454 of NRS, to or for himself or herself or to  
8 others except as authorized by law.

9 (d) Performing, assisting or advising the injection of any substance containing  
10 liquid silicone into the human body, except for the use of silicone oil to repair a  
11 retinal detachment.

12 (e) Practicing or offering to practice beyond the scope permitted by law or  
13 performing services which the licensee knows or has reason to know that he or she  
14 is not competent to perform or which are beyond the scope of his or her training.

15 (f) Performing, without first obtaining the informed consent of the patient or  
16 the patient's family, any procedure or prescribing any therapy which by the current  
17 standards of the practice of medicine is experimental.

18 (g) Continual failure to exercise the skill or diligence or use the methods  
19 ordinarily exercised under the same circumstances by physicians in good standing  
20 practicing in the same specialty or field.

21 (h) Having an alcohol or other substance use disorder.

22 (i) Making or filing a report which the licensee or applicant knows to be false  
23 or failing to file a record or report as required by law or regulation.

24 (j) Failing to comply with the requirements of NRS 630.254.

25 (k) Failure by a licensee or applicant to report in writing, within 30 days, any  
26 disciplinary action taken against the licensee or applicant by another state, the  
27 Federal Government or a foreign country, including, without limitation, the  
28 revocation, suspension or surrender of a license to practice medicine in another  
29 jurisdiction. The provisions of this paragraph do not apply to any disciplinary  
30 action taken by the Board or taken because of any disciplinary action taken by the  
31 Board.

32 (l) Failure by a licensee or applicant to report in writing, within 30 days, any  
33 criminal action taken or conviction obtained against the licensee or applicant, other  
34 than a minor traffic violation, in this State or any other state or by the Federal  
35 Government, a branch of the Armed Forces of the United States or any local or  
36 federal jurisdiction of a foreign country.

37 (m) Failure to be found competent to practice medicine as a result of an  
38 examination to determine medical competency pursuant to NRS 630.318.

39 (n) Operation of a medical facility at any time during which:

40 (1) The license of the facility is suspended or revoked; or

41 (2) An act or omission occurs which results in the suspension or revocation  
42 of the license pursuant to NRS 449.160.

43 ➤ This paragraph applies to an owner or other principal responsible for the  
44 operation of the facility.

45 (o) Failure to comply with the requirements of NRS 630.373.

46 (p) Engaging in any act that is unsafe or unprofessional conduct in accordance  
47 with regulations adopted by the Board.

48 (q) Knowingly or willfully procuring or administering a controlled substance  
49 or a dangerous drug as defined in chapter 454 of NRS that is not approved by the  
50 United States Food and Drug Administration, unless the unapproved controlled  
51 substance or dangerous drug:

52 (1) Was procured through a retail pharmacy licensed pursuant to chapter  
53 639 of NRS;

(2) Was procured through a Canadian pharmacy which is licensed pursuant to chapter 639 of NRS and which has been recommended by the State Board of Pharmacy pursuant to subsection 4 of NRS 639.2328;

(3) Is cannabis being used for medical purposes in accordance with chapter 678C of NRS; or

(4) Is an *individualized investigational treatment or* investigational drug or biological product prescribed to a patient pursuant to NRS 630.3735 or 633.6945.

(r) Failure to supervise adequately a medical assistant pursuant to the regulations of the Board.

(s) Failure to comply with the provisions of NRS 630.3745.

(t) Failure to obtain any training required by the Board pursuant to NRS 630.2535.

(u) Failure to comply with the provisions of NRS 454.217 or 629.086.

(v) Failure to comply with the provisions of NRS 441A.315 or any regulations adopted pursuant thereto.

(w) Performing or supervising the performance of a pelvic examination in violation of NRS 629.085.

2. As used in this section ~~[, “investigational”]~~ :

(a) *“Individualized investigational treatment” has the meaning ascribed to it in NRS 454.690.*

(b) *“Investigational drug or biological product” has the meaning ascribed to it in NRS 454.351.*

**Sec. 4.** NRS 630.3735 is hereby amended to read as follows:

630.3735 1. A physician may prescribe or recommend an *individualized investigational treatment or* investigational drug, biological product or device to a patient if the physician has:

(a) Diagnosed the patient with a ~~[terminal]~~ *life-threatening or severely debilitating disease or* condition;

(b) Discussed with the patient all available methods of treating the ~~[terminal]~~ *life-threatening or severely debilitating disease or* condition that have been approved by the United States Food and Drug Administration and the patient and the physician have determined that no such method of treatment is adequate to treat the ~~[terminal]~~ *life-threatening or severely debilitating disease or* condition of the patient; ~~[and]~~

(c) *For an individualized investigational treatment, conducted an analysis of the patient’s genomic sequence, human chromosomes, deoxyribonucleic acid, ribonucleic acid, genes, gene products or metabolites ~~[,]~~ or an immunity panel, as applicable to the individualized investigational treatment; and*

(d) Obtained informed, written consent to the use of the *individualized investigational treatment or* investigational drug, biological product or device , as applicable, from:

(1) The patient;

(2) If the patient is incompetent, the representative of the patient; or

(3) If the patient is less than 18 years of age, a parent or legal guardian of the patient.

2. An informed, written consent must be recorded on a form signed by the patient, or the representative or parent or legal guardian of the patient, as applicable ~~[, that contains:]~~ The form must:

(a) ~~[An]~~ To the extent practicable, be in the preferred language of the patient, or the representative or parent or legal guardian of the patient, as applicable.

(b) Be in language that is at the reading level of an eighth grader or a pupil enrolled in a lower grade.

(c) Include or be accompanied by:

(1) An overview of the provisions of this section and NRS 454.690, including, without limitation, a detailed description of the provisions of subsection 1 and the terms defined in subsection 8;

(2) A ~~comprehensive~~ explanation of all methods of treating the ~~terminal~~ life-threatening or severely debilitating disease or condition of the patient that are currently approved by the United States Food and Drug Administration ~~and~~, including, without limitation, information concerning such methods published by the United States Food and Drug Administration, the National Institutes of Health or other federal agencies;

~~(3)~~ (3) A statement that the patient, or the representative or parent or legal guardian of the patient, as applicable, and the physician agree that no such method is likely to ~~significantly prolong the life~~ adequately treat the life-threatening or severely debilitating disease or condition of the patient;

~~(4)~~ (4) Clear identification of the specific individualized investigational treatment or investigational drug, biological product or device proposed to treat the ~~terminal~~ life-threatening or severely debilitating disease or condition of the patient;

~~(5)~~ (5) A detailed description of the consequences of using the individualized investigational treatment or investigational drug, biological product or device, which must include, without limitation:

~~(1)~~ (I) A detailed description of the best and worst possible outcomes;

~~(2)~~ (II) A realistic and detailed description of the most likely outcome, in the opinion of the physician;

(III) A detailed description of relevant information that is not known about the individualized investigational treatment or investigational drug, biological product or device; and

~~(3)~~ (IV) A statement of the possibility that using the individualized investigational treatment or investigational drug, biological product or device may result in new, unanticipated, different or worse symptoms or the death of the patient occurring sooner than if the individualized investigational treatment or investigational drug, biological product or device is not used ~~and~~ and a detailed description of any known new, different or worse symptoms the patient may suffer;

(6) A statement of the rights of the patient, including, without limitation, the rights to:

(I) Make an informed decision concerning the use of the individualized investigational treatment or investigational drug, biological product or device; and

(II) Withdraw from or refuse treatment using the individualized investigational treatment or investigational drug, biological product or device at any time;

(7) Information concerning resources that may be useful to the patient, including, without limitation, the contact information for agencies or organizations that may be able to provide support to the patient;

(8) A means by which the patient may contact the manufacturer of the individualized investigational treatment or investigational drug, biological product or device with any additional questions or concerns;

~~(9)~~ (9) A statement that a health insurer of the patient may not be required to pay for care or treatment of any condition resulting from the use of the individualized investigational treatment or investigational drug, biological product

or device unless such care or treatment is specifically included in the policy of insurance covering the patient and that future benefits under the policy of insurance covering the patient may be affected by the patient's use of the *individualized investigational treatment or* investigational drug, biological product or device; and ~~(10)~~ (10) A statement that the patient, or the representative or parent or legal guardian of the patient, as applicable, understands that the patient is liable for all costs resulting from the use of the *individualized investigational treatment or* investigational drug, biological product or device, including, without limitation, costs resulting from care or treatment of any condition resulting from the use of the *individualized investigational treatment or* investigational drug, biological product or device, and that such liability will be passed on to the estate of the patient upon the death of the patient.

3. A physician who prescribes or recommends an individualized investigational treatment or investigational drug, biological product or device to a patient shall provide to the patient a form that:

(a) To the extent practicable, is in the preferred language of the patient; and

(b) Contains:

(1) The name of the individualized investigational treatment or investigational drug, biological product or device;

(2) The instructions for use and, where applicable, the recommended dosage of the individualized investigational treatment or investigational drug, biological product or device;

(3) Where applicable, the investigational new drug number assigned by the United States Food and Drug Administration;

(4) The telephone number for the hotline established pursuant to subsection 4 of NRS 454.690;

(5) The contact information, telephone number, hours of operation and physical address of an emergency room or urgent care facility that is easily accessible to the patient if the patient experiences an adverse effect or symptom; and

(6) Any other information concerning the individualized investigational treatment or investigational drug, biological product or device that is relevant to the care of the patient.

4. Not later than 72 hours after the death or hospitalization of a patient which results from the use of an individualized investigational treatment or investigational drug, biological product or device, the physician who prescribed or recommended the individualized investigational treatment or investigational drug, biological product or device shall notify the Board.

5. On or before January 31 of each odd-numbered year, the Board shall submit to the Director of the Legislative Counsel Bureau for transmittal to the next regular session of the Legislature a summary of the information reported to the Board pursuant to subsection 4 and subsection 4 of NRS 454.690 during the immediately preceding biennium.

6. A physician is not subject to disciplinary action for prescribing or recommending an individualized investigational treatment or investigational drug, biological product or device when authorized to do so pursuant to subsection 1.

7. The Board may adopt regulations to ensure the safety and efficacy of individualized investigational treatments and investigational drugs, biological products and devices prescribed or recommended pursuant to this section.

~~(8)~~ 8. As used in this section:

(a) *"Individualized investigational treatment"* has the meaning ascribed to it in NRS 454.690.

1 (b) "Investigational drug, biological product or device" has the meaning  
2 ascribed to it in NRS 454.690.

3 ~~[(b) "Terminal condition"]~~

4 (c) "*Life-threatening disease or condition*" has the meaning ascribed to it in  
5 NRS 454.690.

6 (d) "*Severely debilitating disease or condition*" has the meaning ascribed to  
7 it in NRS 454.690.

8 **Sec. 5.** NRS 632.347 is hereby amended to read as follows:

9 632.347 1. The Board may deny, revoke or suspend any license or  
10 certificate applied for or issued pursuant to this chapter, or take other disciplinary  
11 action against a licensee or holder of a certificate, upon determining that the  
12 licensee or certificate holder:

13 (a) Is guilty of fraud or deceit in procuring or attempting to procure a license or  
14 certificate pursuant to this chapter.

15 (b) Is guilty of any offense:

16 (1) Involving moral turpitude; or

17 (2) Related to the qualifications, functions or duties of a licensee or holder  
18 of a certificate,

19 in which case the record of conviction is conclusive evidence thereof.

20 (c) Has been convicted of violating any of the provisions of NRS 616D.200,  
21 616D.220, 616D.240 or 616D.300 to 616D.440, inclusive.

22 (d) Is unfit or incompetent by reason of gross negligence or recklessness in  
23 carrying out usual nursing functions.

24 (e) Uses any controlled substance, dangerous drug as defined in chapter 454 of  
25 NRS, or intoxicating liquor to an extent or in a manner which is dangerous or  
26 injurious to any other person or which impairs his or her ability to conduct the  
27 practice authorized by the license or certificate.

28 (f) Is a person with mental incompetence.

29 (g) Is guilty of unprofessional conduct, which includes, but is not limited to,  
30 the following:

31 (1) Conviction of practicing medicine without a license in violation of  
32 chapter 630 of NRS, in which case the record of conviction is conclusive evidence  
33 thereof.

34 (2) Impersonating any applicant or acting as proxy for an applicant in any  
35 examination required pursuant to this chapter for the issuance of a license or  
36 certificate.

37 (3) Impersonating another licensed practitioner or holder of a certificate.

38 (4) Permitting or allowing another person to use his or her license or  
39 certificate to practice as a licensed practical nurse, registered nurse, nursing  
40 assistant or medication aide - certified.

41 (5) Repeated malpractice, which may be evidenced by claims of  
42 malpractice settled against the licensee or certificate holder.

43 (6) Physical, verbal or psychological abuse of a patient.

44 (7) Conviction for the use or unlawful possession of a controlled substance  
45 or dangerous drug as defined in chapter 454 of NRS.

46 (h) Has willfully or repeatedly violated the provisions of this chapter. The  
47 voluntary surrender of a license or certificate issued pursuant to this chapter is  
48 prima facie evidence that the licensee or certificate holder has committed or expects  
49 to commit a violation of this chapter.

50 (i) Is guilty of aiding or abetting any person in a violation of this chapter.

51 (j) Has falsified an entry on a patient's medical chart concerning a controlled  
52 substance.

(k) Has falsified information which was given to a physician, pharmacist, podiatric physician or dentist to obtain a controlled substance.

(l) Has knowingly procured or administered a controlled substance or a dangerous drug as defined in chapter 454 of NRS that is not approved by the United States Food and Drug Administration, unless the unapproved controlled substance or dangerous drug:

(1) Was procured through a retail pharmacy licensed pursuant to chapter 639 of NRS;

(2) Was procured through a Canadian pharmacy which is licensed pursuant to chapter 639 of NRS and which has been recommended by the State Board of Pharmacy pursuant to subsection 4 of NRS 639.2328;

(3) Is cannabis being used for medical purposes in accordance with chapter 678C of NRS; or

(4) Is an *individualized investigational treatment* or investigational drug or biological product prescribed to a patient pursuant to NRS 630.3735 or 633.6945.

(m) Has been disciplined in another state in connection with a license to practice nursing or a certificate to practice as a nursing assistant or medication aide - certified, or has committed an act in another state which would constitute a violation of this chapter.

(n) Has engaged in conduct likely to deceive, defraud or endanger a patient or the general public.

(o) Has willfully failed to comply with a regulation, subpoena or order of the Board.

(p) Has operated a medical facility at any time during which:

(1) The license of the facility was suspended or revoked; or

(2) An act or omission occurred which resulted in the suspension or revocation of the license pursuant to NRS 449.160.

➤ This paragraph applies to an owner or other principal responsible for the operation of the facility.

(q) Is an advanced practice registered nurse who has failed to obtain any training required by the Board pursuant to NRS 632.2375.

(r) Is an advanced practice registered nurse who has failed to comply with the provisions of NRS 453.163, 453.164, 453.226, 639.23507, 639.23535 and 639.2391 to 639.23916, inclusive, and any regulations adopted by the State Board of Pharmacy pursuant thereto.

(s) Has engaged in the fraudulent, illegal, unauthorized or otherwise inappropriate prescribing, administering or dispensing of a controlled substance listed in schedule II, III or IV.

(t) Has violated the provisions of NRS 454.217 or 629.086.

(u) Has performed or supervised the performance of a pelvic examination in violation of NRS 629.085.

(v) Has failed to comply with the provisions of NRS 441A.315 or any regulations adopted pursuant thereto.

2. For the purposes of this section, a plea or verdict of guilty or guilty but mentally ill or a plea of nolo contendere constitutes a conviction of an offense. The Board may take disciplinary action pending the appeal of a conviction.

3. A licensee or certificate holder is not subject to disciplinary action solely for administering auto-injectable epinephrine pursuant to a valid order issued pursuant to NRS 630.374 or 633.707.

4. As used in this section ~~[, “investigational”]~~ :

(a) *“Individualized investigational treatment” has the meaning ascribed to it in NRS 454.690.*

1       (b) “*Investigational* drug or biological product” has the meaning ascribed to it  
2 in NRS 454.351.

3       **Sec. 6.** NRS 633.511 is hereby amended to read as follows:

4       633.511 1. The grounds for initiating disciplinary action pursuant to this  
5 chapter are:

6       (a) Unprofessional conduct.

7       (b) Conviction of:

8       (1) A violation of any federal or state law regulating the possession,  
9 distribution or use of any controlled substance or any dangerous drug as defined in  
10 chapter 454 of NRS;

11       (2) A felony relating to the practice of osteopathic medicine or practice as  
12 a physician assistant;

13       (3) A violation of any of the provisions of NRS 616D.200, 616D.220,  
14 616D.240 or 616D.300 to 616D.440, inclusive;

15       (4) Murder, voluntary manslaughter or mayhem;

16       (5) Any felony involving the use of a firearm or other deadly weapon;

17       (6) Assault with intent to kill or to commit sexual assault or mayhem;

18       (7) Sexual assault, statutory sexual seduction, incest, lewdness, indecent  
19 exposure or any other sexually related crime;

20       (8) Abuse or neglect of a child or contributory delinquency; or

21       (9) Any offense involving moral turpitude.

22       (c) The suspension of a license to practice osteopathic medicine or to practice  
23 as a physician assistant by any other jurisdiction.

24       (d) Malpractice or gross malpractice, which may be evidenced by a claim of  
25 malpractice settled against a licensee.

26       (e) Professional incompetence.

27       (f) Failure to comply with the requirements of NRS 633.527.

28       (g) Failure to comply with the requirements of subsection 3 of NRS 633.471.

29       (h) Failure to comply with the provisions of NRS 633.694.

30       (i) Operation of a medical facility, as defined in NRS 449.0151, at any time  
31 during which:

32       (1) The license of the facility is suspended or revoked; or

33       (2) An act or omission occurs which results in the suspension or revocation  
34 of the license pursuant to NRS 449.160.

35       ➤ This paragraph applies to an owner or other principal responsible for the  
36 operation of the facility.

37       (j) Failure to comply with the provisions of subsection 2 of NRS 633.322.

38       (k) Signing a blank prescription form.

39       (l) Knowingly or willfully procuring or administering a controlled substance or  
40 a dangerous drug as defined in chapter 454 of NRS that is not approved by the  
41 United States Food and Drug Administration, unless the unapproved controlled  
42 substance or dangerous drug:

43       (1) Was procured through a retail pharmacy licensed pursuant to chapter  
44 639 of NRS;

45       (2) Was procured through a Canadian pharmacy which is licensed pursuant  
46 to chapter 639 of NRS and which has been recommended by the State Board of  
47 Pharmacy pursuant to subsection 4 of NRS 639.2328;

48       (3) Is cannabis being used for medical purposes in accordance with chapter  
49 678C of NRS; or

50       (4) Is an *individualized investigational treatment or* investigational drug  
51 or biological product prescribed to a patient pursuant to NRS 630.3735 or  
52 633.6945.



(m) Attempting, directly or indirectly, by intimidation, coercion or deception, to obtain or retain a patient or to discourage the use of a second opinion.

(n) Terminating the medical care of a patient without adequate notice or without making other arrangements for the continued care of the patient.

(o) In addition to the provisions of subsection 3 of NRS 633.524, making or filing a report which the licensee knows to be false, failing to file a record or report that is required by law or knowingly or willfully obstructing or inducing another to obstruct the making or filing of such a record or report.

(p) Failure to report any person the licensee knows, or has reason to know, is in violation of the provisions of this chapter, except for a violation of NRS 633.4717, or the regulations of the Board within 30 days after the date the licensee knows or has reason to know of the violation.

(q) Failure by a licensee or applicant to report in writing, within 30 days, any criminal action taken or conviction obtained against the licensee or applicant, other than a minor traffic violation, in this State or any other state or by the Federal Government, a branch of the Armed Forces of the United States or any local or federal jurisdiction of a foreign country.

(r) Engaging in any act that is unsafe in accordance with regulations adopted by the Board.

(s) Failure to comply with the provisions of NRS 629.515.

(t) Failure to supervise adequately a medical assistant pursuant to the regulations of the Board.

(u) Failure to obtain any training required by the Board pursuant to NRS 633.473.

(v) Failure to comply with the provisions of NRS 633.6955.

(w) Failure to comply with the provisions of NRS 453.163, 453.164, 453.226, 639.23507, 639.23535 and 639.2391 to 639.23916, inclusive, and any regulations adopted by the State Board of Pharmacy pursuant thereto.

(x) Fraudulent, illegal, unauthorized or otherwise inappropriate prescribing, administering or dispensing of a controlled substance listed in schedule II, III or IV.

(y) Failure to comply with the provisions of NRS 454.217 or 629.086.

(z) Failure to comply with the provisions of NRS 441A.315 or any regulations adopted pursuant thereto.

(aa) Performing or supervising the performance of a pelvic examination in violation of NRS 629.085.

2. As used in this section ~~[, “investigational”]~~ :

(a) *“Individualized investigational treatment” has the meaning ascribed to it in NRS 454.690.*

(b) *“Investigational drug or biological product” has the meaning ascribed to it in NRS 454.351.*

**Sec. 7.** NRS 633.6945 is hereby amended to read as follows:

633.6945 1. An osteopathic physician may prescribe or recommend an *individualized investigational treatment or* investigational drug, biological product or device to a patient if the osteopathic physician has:

(a) Diagnosed the patient with a ~~[terminal]~~ *life-threatening or severely debilitating disease or* condition;

(b) Discussed with the patient all available methods of treating the ~~[terminal]~~ *life-threatening or severely debilitating disease or* condition that have been approved by the United States Food and Drug Administration and the patient and the osteopathic physician have determined that no such method of treatment is adequate to treat the ~~[terminal]~~ *life-threatening or severely debilitating disease or* condition of the patient; ~~[and]~~



(c) *For an individualized investigational treatment, conducted an analysis of the patient's genomic sequence, human chromosomes, deoxyribonucleic acid, ribonucleic acid, genes, gene products or metabolites ~~or~~ or an immunity panel, as applicable to the individualized investigational treatment; and*

(d) Obtained informed, written consent to the use of the *individualized investigational treatment or* investigational drug, biological product or device, *as applicable*, from:

- (1) The patient;
- (2) If the patient is incompetent, the representative of the patient; or
- (3) If the patient is less than 18 years of age, a parent or legal guardian of the patient.

2. An informed, written consent must be recorded on a form signed by the patient, or the representative or parent or legal guardian of the patient, as applicable ~~that contains:~~ The form must:

(a) ~~An~~ To the extent practicable, be in the preferred language of the patient, or the representative or parent or legal guardian of the patient, as applicable.

(b) Be in language that is at the reading level of an eighth grader or a pupil enrolled in a lower grade.

(c) Include or be accompanied by:

(I) An overview of the provisions of this section and NRS 454.690, including, without limitation, a detailed description of the provisions of subsection 1 and the terms defined in subsection 8;

(2) A comprehensive explanation of all methods of treating the ~~terminal~~ life-threatening or severely debilitating disease or condition of the patient that are currently approved by the United States Food and Drug Administration ~~or~~, including, without limitation, information concerning such methods published by the United States Food and Drug Administration, the National Institutes of Health or other federal agencies;

~~(3)~~ (3) A statement that the patient, or the representative or parent or legal guardian of the patient, as applicable, and the osteopathic physician agree that no such method is likely to ~~significantly prolong the life~~ adequately treat the life-threatening or severely debilitating disease or condition of the patient;

~~(4)~~ (4) Clear identification of the specific *individualized investigational treatment or* investigational drug, biological product or device proposed to treat the ~~terminal~~ life-threatening or severely debilitating disease or condition of the patient;

~~(5)~~ (5) A detailed description of the consequences of using the *individualized investigational treatment or* investigational drug, biological product or device, which must include, without limitation:

~~(1)~~ (I) A detailed description of the best and worst possible outcomes;

~~(2)~~ (II) A realistic and detailed description of the most likely outcome, in the opinion of the osteopathic physician;

(III) A detailed description of relevant information that is not known about the individualized investigational treatment or investigational drug, biological product or device; and

~~(3)~~ (IV) A statement of the possibility that using the *individualized investigational treatment or* investigational drug, biological product or device may result in new, unanticipated, different or worse symptoms or the death of the patient occurring sooner than if the *individualized investigational treatment or* investigational drug, biological product or device is not used ~~or~~ and a detailed description of any known new, different or worse symptoms the patient may suffer;

(6) A statement of the rights of the patient, including, without limitation, the rights to:

(I) Make an informed decision concerning the use of the individualized investigational treatment or investigational drug, biological product or device; and

(II) Withdraw from or refuse treatment using the individualized investigational treatment or investigational drug, biological product or device at any time;

(7) Information concerning resources that may be useful to the patient, including, without limitation, the contact information for agencies or organizations that may be able to provide support to the patient;

(8) A means by which the patient may contact the manufacturer of the individualized investigational treatment or investigational drug, biological product or device with any additional questions or concerns;

~~[(6)]~~ (9) A statement that a health insurer of the patient may not be required to pay for care or treatment of any condition resulting from the use of the individualized investigational treatment or investigational drug, biological product or device unless such care or treatment is specifically included in the policy of insurance covering the patient and that future benefits under the policy of insurance covering the patient may be affected by the patient's use of the individualized investigational treatment or investigational drug, biological product or device; and

~~[(6)]~~ (10) A statement that the patient, or the representative or parent or legal guardian of the patient, as applicable, understands that the patient is liable for all costs resulting from the use of the individualized investigational treatment or investigational drug, biological product or device, including, without limitation, costs resulting from care or treatment of any condition resulting from the use of the individualized investigational treatment or investigational drug, biological product or device, and that such liability will be passed on to the estate of the patient upon the death of the patient.

3. An osteopathic physician who prescribes or recommends an individualized investigational treatment or investigational drug, biological product or device to a patient shall provide to the patient a form that:

(a) To the extent practicable, is in the preferred language of the patient; and

(b) Contains:

(1) The name of the individualized investigational treatment or investigational drug, biological product or device;

(2) The instructions for use and, where applicable, the recommended dosage of the individualized investigational treatment or investigational drug, biological product or device;

(3) Where applicable, the investigational new drug number assigned by the United States Food and Drug Administration;

(4) The telephone number for the hotline established pursuant to subsection 4 of NRS 454.690;

(5) The contact information, telephone number, hours of operation and physical address of an emergency room or urgent care facility that is easily accessible to the patient if the patient experiences an adverse effect or symptom; and

(6) Any other information concerning the individualized investigational treatment or investigational drug, biological product or device that is relevant to the care of the patient.

4. Not later than 72 hours after the death or hospitalization of a patient which results from the use of an individualized investigational treatment or investigational drug, biological product or device, the osteopathic physician who

prescribed or recommended the individualized investigational treatment or investigational drug, biological product or device shall notify the Board.

5. On or before January 31 of each odd-numbered year, the Board shall submit to the Director of the Legislative Counsel Bureau for transmittal to the next regular session of the Legislature a summary of the information reported to the Board pursuant to subsection 4 and subsection 4 of NRS 454.690 during the immediately preceding biennium.

6. An osteopathic physician is not subject to disciplinary action for prescribing or recommending an individualized investigational treatment or investigational drug, biological product or device when authorized to do so pursuant to subsection 1.

7. The Board may adopt regulations to ensure the safety and efficacy of individualized investigational treatments and investigational drugs, biological products and devices prescribed or recommended pursuant to this section.

~~44~~ 8. As used in this section:

(a) *“Individualized investigational treatment” has the meaning ascribed to it in NRS 454.690.*

(b) *“Investigational drug, biological product or device” has the meaning ascribed to it in NRS 454.690.*

~~(b) “Terminal condition”~~

(c) *“Life-threatening disease or condition” has the meaning ascribed to it in NRS 454.690.*

(d) *“Severely debilitating disease or condition” has the meaning ascribed to it in NRS 454.690.*

Sec. 7.3. The provisions of subsection 1 of NRS 218D.380 do not apply to any provision of this act which adds or revises a requirement to submit a report to the Legislature.

Sec. 7.5. 1. A patient who is being treated with an individualized investigational treatment or an investigational drug, biological product or device on June 30, 2027, may continue to receive such treatment on and after July 1, 2027, regardless of whether the patient remains eligible to receive such treatment.

2. As used in this section:

(a) “Individualized investigational treatment” has the meaning ascribed to it in NRS 454.690, as amended by section 2 of this act.

(b) “Investigational drug, biological product or device” has the meaning ascribed to it in NRS 454.690, as amended by section 2 of this act.

Sec. 8. 1. This act becomes effective on July 1, 2023.

2. Sections 1 to 7, inclusive, of this act expire by limitation on July 1, 2027.